🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

IDEX shares target cut by Oppenheimer amid organic sales decline

EditorEmilio Ghigini
Published 08/05/2024, 08:30 AM
IEX
-

On Monday, Oppenheimer adjusted its outlook on IDEX Corp (NYSE:IEX) shares, reducing the price target to $238 from the previous $245, while maintaining an Outperform rating on the stock.

The adjustment follows IDEX's second-quarter earnings report, which revealed an adjusted earnings per share (EPS) of $2.06, surpassing the estimated $2.04. This beat was attributed to a favorable impact from below-the-line items.

IDEX's operational results slightly missed expectations, except for a notable improvement in HST margin, which showed a year-over-year increase of 10 basis points and a 100 basis points rise over Oppenheimer's estimates.

However, the company's consolidated revenue saw a 5% year-over-year decrease, with a 4% organic decline. This downturn was largely due to a persistent weakness in core HST sales, which fell by 11%.

Despite a modest 1% growth in orders, with a 2% organic increase, IDEX revised its 2024 organic sales guidance downward, now anticipating a 1-2% year-over-year decrease, adjusted from the previously expected flat to 2% growth. The company also updated its adjusted EPS forecast to $7.80-7.90, a cut from the prior $8.15-8.45 range.

The report suggests that although the headwinds in the HST segment continue to impact IDEX's growth and profitability, the current valuation of the company, with a forward price-to-earnings (P/E) ratio in the low to mid-20s, could be seen as reasonably supportive.

This assessment hinges on the expectation of a recovery in key HST platforms as the company moves into 2025. Additionally, the potential for accretive mergers and acquisitions, including the recent acquisition of Mott, is seen as offering upside potential to the firm's financial modeling and valuation rationale.

InvestingPro Insights

Following Oppenheimer's updated outlook on IDEX Corp, real-time data from InvestingPro provides additional context to the company's financial health and market performance. IDEX Corp, with a market capitalization of $14.7 billion as of Q2 2024, is trading at a P/E ratio of 25.38, reflecting a premium valuation compared to the industry average. The company's commitment to shareholder returns is evident as it has raised its dividend for 14 consecutive years and has maintained dividend payments for 30 consecutive years, showcasing a strong track record of financial stability and investor confidence.

InvestingPro Tips highlight that IDEX is currently trading near its 52-week low, potentially presenting an opportunity for investors considering the company's history of profitability over the last twelve months. However, analysts have revised their earnings downwards for the upcoming period, signaling caution. Additionally, with a dividend yield of 1.42% and a recent dividend growth of 7.81%, the company demonstrates a balance between returning value to shareholders and reinvesting in its operations.

For readers looking to delve deeper into IDEX's financials and market potential, additional InvestingPro Tips are available, offering insights into the company's performance and future outlook. Visit the dedicated InvestingPro page for IDEX Corp for a comprehensive analysis and more expert tips.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.